Specifically, we found coordinated activities through which Cav1 rewires prostate cancer cells towards exogenous scavenging of sphingomyelin, increased cancer cell catabolism of sphingomyelin to ceramide, and subsequent glycosylation to glycosphingolipid derivatives [13]. The gene discussed is CAV1; the disease is Familial prostate cancer.